NeoGenomics (STU:NG9) Total Payout Ratio : 0.07 (As of Dec. 14, 2024)

View and export this data going back to 2016. Start your Free Trial

What is NeoGenomics Total Payout Ratio?

Total Payout Ratio is the percent a company has paid to its shareholders through net repurchase of shares and dividends based on its Net Income.

NeoGenomics's current Total Payout Ratio is 0.07.

NeoGenomics Total Payout Ratio Historical Data

The historical data trend for NeoGenomics's Total Payout Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

NeoGenomics Total Payout Ratio Chart

NeoGenomics Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Total Payout Ratio

Get a 7-Day Free Trial

-21.48

-35.38

50.70

0.09

0.05

NeoGenomics Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
Total Payout Ratio	Get a 7-Day Free Trial															0.10	0.09	0.03	0.11	0.07

Competitive Comparison of NeoGenomics's Total Payout Ratio

For the Diagnostics & Research subindustry, NeoGenomics's Total Payout Ratio, along with its competitors' market caps and Total Payout Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

NeoGenomics's Total Payout Ratio Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, NeoGenomics's Total Payout Ratio distribution charts can be found below:

* The bar in red indicates where NeoGenomics's Total Payout Ratio falls into.

NeoGenomics Total Payout Ratio Calculation

Total Payout Ratio is a measurement showing the proportion of earnings a company pays shareholders in the form of dividends and net stock repurchases.

NeoGenomics's Total Payout Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Total Payout Ratio	=	- (Repurchase of Stock	+	Issuance of Stock	+	Cash Flow for Dividends)	/	Net Income
	=	- (0	+	4.24	+	0)	/	-80.667
	=	0.05

NeoGenomics's Total Payout Ratio for the quarter that ended in Sep. 2024 is calculated as

Total Payout Ratio	=	- (Repurchase of Stock	+	Issuance of Stock	+	Cash Flow for Dividends)	/	Net Income
	=	- (0	+	1.06	+	0)	/	-15.947
	=	0.07

NeoGenomics Total Payout Ratio Related Terms

Thank you for viewing the detailed overview of NeoGenomics's Total Payout Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.

NeoGenomics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » NeoGenomics Inc (STU:NG9) » Definitions » Total Payout Ratio

Comparable Companies

TWST MYGN CDNA VCYT OPK NEOG CSTL SHC GRAL FLGT TMO DHR XSWX:LONN A IQV IDXX MTD ILMN WAT NTRA

Traded in Other Exchanges

NEO:USA NG9:Germany

Address

9490 NeoGenomics Way, Fort Myers, FL, USA, 33912

Website

https://www.neogenomics.com

NeoGenomics Inc operates a network of cancer-focused genetic testing laboratories in the United States as well as a laboratory in Switzerland. The company operates into two segments namely Clinical Services and Advanced Diagnostics. It offers types of genetic and molecular testing services namely Cytogenetics, Fluorescence In-Situ Hybridization, Flow cytometry, Immunohistochemistry, Molecular testing, Pathology consultation. Advanced Diagnostics segment supports pharmaceutical firms in their drug development programs by supporting various clinical trials and research. For Clinical Services, Its specialized diagnostic services are performed based on an online test order or a written test requisition form. The company generates majority of its revenue from Clinical Services.

NeoGenomics Headlines

No Headlines